Ironwood Pharmaceuticals
Présence
Ironwood Pharmaceuticals fait partie des...
Ironwood Pharmaceuticals est une société cotée sous le symbole boursier IRWD (US).
Ironwood Pharmaceuticals a une présence directe dans 2 pays.
Elles sont en:
- Pharmacie50%
- Biotechnologie50%
Acquisition, funding and merger involving Ironwood Pharmaceuticals.
- Ironwood Pharmaceuticals has announced the acquisition of VectivBio (publié le 25 mai 2023).
Dirigeants
Voir l'organigramme avec ses 38 principaux dirigeants
Biographies les plus recherchées chez Ironwood Pharmaceuticals
- Thomas McCourt, Chief Executive Officer and Director
- Julie McHugh, Chairman of the Board
- Catherine Moukheibir, Director
Créer une alerte
pour suivre les mouvements de dirigeants chez Ironwood Pharmaceuticals.
Pharmacie
Ironwood Pharmaceuticals a 1 861 concurrents dont Pfizer (Etats—Unis), Sanofi (France) et Johnson & Johnson (Etats—Unis).
Actualités en fusion/acquisition en Pharmacie.
- MedMen has filed for bankruptcy protection (publié le 28 avril 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publié le 23 mars 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publié le 19 mars 2024).
Contacts en Pharmacie
Actualités
Derniers communiqués de presse par Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
- Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)
- Ironwood Pharmaceuticals Announces Positive Topline Results from Global Phase III Trial of Once-Weekly Apraglutide in Adults with Short Bowel Syndrome with Intestinal Failure (SBS-IF)
- Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
- Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results; Achieves 2023 Financial Guidance
- Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation
- Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
- Ironwood Pharmaceuticals Maintains FY 2023 Financial Guidance and Announces FY 2024 Financial Guidance
- Ironwood Pharmaceuticals Reports Second Quarter 2023 Results; Raises Full Year 2023 LINZESS® U.S. Net Sales and Ironwood Revenue Guidance
- Voir plus de communiqués de presse Close
Réseaux sociaux à propos de Ironwood Pharmaceuticals
- Ironwood Pharmaceuticals sur Wikipédia, Google News & Yahoo Finance en 1-click
- Ironwood Pharmaceuticals sur LinkedIn, Twitter & YouTube en 1-click
